Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis

• Status: Completed
• Trial end date: 2018-08-13
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the use of single agent ublituximab, a novel monoclonal antibody, in participants with relapsing forms of multiple sclerosis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: TG Therapeutics, Inc.

Criteria

Inclusion Criteria:

• Diagnosis of relapsing multiple sclerosis

• Active disease

• Greater than or equal to (≥) 2 relapses in prior 2 years or 1 relapse in the year prior to screening and/or ≥1 gadolinium (Gd) enhancing lesion

Exclusion Criteria:

• Treatment with anti-cluster of differentiation 20 (CD20) monoclonal antibody within the last 12 months

• Treatment with alemtuzumab within the last 12 months

• Pregnant or nursing mothers